Published in Med Mycol on June 11, 2012
Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis. Int J Infect Dis (2014) 0.84
Efficacy of Amphotericin B at Suboptimal Dose Combined with Voriconazole in a Murine Model of Aspergillus fumigatus Infection with Poor In Vivo Response to the Azole. Antimicrob Agents Chemother (2013) 0.81
Better hospital nutrition needed to prevent and treat Aspergillus infections. Med Mycol (2012) 0.75
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis (2009) 18.19
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med (2002) 17.04
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 16.51
Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS (2009) 16.37
Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis (2005) 13.97
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis (2010) 11.65
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis (2011) 9.37
Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med (2010) 7.20
Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med (2010) 6.26
Persistence of Ebola Virus in Ocular Fluid during Convalescence. N Engl J Med (2015) 5.92
Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med (2007) 5.88
Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis (2012) 5.83
Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis (2012) 5.66
Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis (2010) 5.53
Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis (2007) 5.51
Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother (2003) 5.48
Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis (2005) 5.24
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant (2009) 5.10
Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis (2010) 4.98
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis (2006) 4.88
Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis (2009) 4.59
Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol (2004) 4.51
Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis (2006) 4.42
A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis (2003) 4.29
Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA (2008) 4.19
Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med (2008) 4.16
Amphotericin B: time for a new "gold standard". Clin Infect Dis (2003) 4.01
Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis (2007) 3.93
Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis (2009) 3.77
Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis (2003) 3.70
Critical role of Bcr1-dependent adhesins in C. albicans biofilm formation in vitro and in vivo. PLoS Pathog (2006) 3.58
Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis (2006) 3.57
Inhibition of mutation and combating the evolution of antibiotic resistance. PLoS Biol (2005) 3.47
Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood (2002) 3.45
Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot Cell (2005) 3.44
Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect (2012) 3.24
Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis (2004) 3.23
Biofilm matrix regulation by Candida albicans Zap1. PLoS Biol (2009) 3.20
Voriconazole: a new triazole antifungal agent. Clin Infect Dis (2003) 3.19
Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother (2002) 3.18
The serum galactomannan index predicts mortality in hematopoietic stem cell transplant recipients with invasive aspergillosis. Clin Infect Dis (2013) 3.15
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother (2011) 3.04
Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis (2004) 3.01
Use of central venous catheter-related bloodstream infection prevention practices by US hospitals. Mayo Clin Proc (2007) 2.90
Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis (2011) 2.89
Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis (2004) 2.89
Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med (2006) 2.85
A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis (2003) 2.84
Standard versus high-dose CVVHDF for ICU-related acute renal failure. J Am Soc Nephrol (2008) 2.84
Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis (2004) 2.81
Magnetic resonance imaging screening to identify spinal and paraspinal infections associated with injections of contaminated methylprednisolone acetate. JAMA (2013) 2.74
Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infect Dis (2013) 2.71
An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med (2011) 2.70
In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother (2002) 2.67
Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis (2008) 2.65
A recently evolved transcriptional network controls biofilm development in Candida albicans. Cell (2012) 2.56
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis (2006) 2.45
Dectin-1 and TLRs permit macrophages to distinguish between different Aspergillus fumigatus cellular states. J Immunol (2006) 2.43
Preventing hospital-acquired urinary tract infection in the United States: a national study. Clin Infect Dis (2008) 2.42
Complementary adhesin function in C. albicans biofilm formation. Curr Biol (2008) 2.41
Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica (2006) 2.41
Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood (2003) 2.40
Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood (2008) 2.39
Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother (2008) 2.38
Molecular evidence that the range of the Vancouver Island outbreak of Cryptococcus gattii infection has expanded into the Pacific Northwest in the United States. J Infect Dis (2009) 2.37
Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus. Eukaryot Cell (2006) 2.35
Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis (2008) 2.35
Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis (2004) 2.31
Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis (2008) 2.27